Acute Respiratory Distress Syndrome and COVID-19 : A Literature Review
© 2021 Hussain et al..
Acute respiratory distress syndrome (ARDS) is an overwhelming inflammatory disorder of the lung due to direct and indirect insults to the lungs. ARDS is characterized by increased vascular permeability, protein-rich edema, diffuse alveolar infiltrate, and loss of aerated lung tissue, leading to decreased lung compliance, tachypnea, and severe hypoxemia. COVID-19 is generally associated with ARDS, and it has gained prime importance since it started. The mortality rate is alarmingly high in COVID-19-related ARDS patients regardless of advances in mechanical ventilation. Several pharmacological agents, including corticosteroids, nitric oxide, neuromuscular blocker, anti-TNF, statins, and exogenous surfactant, have been studied and some are under investigation, like ketoconazole, lisofylline, N-acetylcysteine, prostaglandins, prostacyclin, and fish oil. The purpose of this review is to appraise the understanding of the pathophysiology of ARDS, biomarkers, and clinical trials of pharmacological therapies of ARDS and COVID-19-related ARDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of inflammation research - 14(2021) vom: 09., Seite 7225-7242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hussain, Musaddique [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lung injury |
|---|
| Anmerkungen: |
Date Revised 08.01.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/JIR.S334043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335277535 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335277535 | ||
| 003 | DE-627 | ||
| 005 | 20231225225451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/JIR.S334043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335277535 | ||
| 035 | |a (NLM)34992415 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hussain, Musaddique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute Respiratory Distress Syndrome and COVID-19 |b A Literature Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.01.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Hussain et al. | ||
| 520 | |a Acute respiratory distress syndrome (ARDS) is an overwhelming inflammatory disorder of the lung due to direct and indirect insults to the lungs. ARDS is characterized by increased vascular permeability, protein-rich edema, diffuse alveolar infiltrate, and loss of aerated lung tissue, leading to decreased lung compliance, tachypnea, and severe hypoxemia. COVID-19 is generally associated with ARDS, and it has gained prime importance since it started. The mortality rate is alarmingly high in COVID-19-related ARDS patients regardless of advances in mechanical ventilation. Several pharmacological agents, including corticosteroids, nitric oxide, neuromuscular blocker, anti-TNF, statins, and exogenous surfactant, have been studied and some are under investigation, like ketoconazole, lisofylline, N-acetylcysteine, prostaglandins, prostacyclin, and fish oil. The purpose of this review is to appraise the understanding of the pathophysiology of ARDS, biomarkers, and clinical trials of pharmacological therapies of ARDS and COVID-19-related ARDS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19-related ARDS | |
| 650 | 4 | |a acute lung injury | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 700 | 1 | |a Khurram Syed, Shahzada |e verfasserin |4 aut | |
| 700 | 1 | |a Fatima, Mobeen |e verfasserin |4 aut | |
| 700 | 1 | |a Shaukat, Saira |e verfasserin |4 aut | |
| 700 | 1 | |a Saadullah, Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Ali M |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Taha |e verfasserin |4 aut | |
| 700 | 1 | |a Bin Emran, Talha |e verfasserin |4 aut | |
| 700 | 1 | |a Alamri, Ali H |e verfasserin |4 aut | |
| 700 | 1 | |a Barkat, Muhammad Qasim |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ximei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of inflammation research |d 2008 |g 14(2021) vom: 09., Seite 7225-7242 |w (DE-627)NLM197692524 |x 1178-7031 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g day:09 |g pages:7225-7242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/JIR.S334043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |b 09 |h 7225-7242 | ||